Oncternal Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Oncternal Therapeutics

05/08/2021 22:02

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 16 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 14 cents per share.
* Revenue rose 41.7% to $883.00 thousand from a year ago; 
analysts expected $1.09 million. 
* The mean earnings estimate of analysts had fallen by
about 22.2% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Oncternal Therapeutics Inc shares had fallen by 21.1% this
quarter and lost 23.5% so far this year.
* Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $16.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 5 at 09:02 p.m.  ​All
figures in US dollars unless otherwise stated